Valneva (Euronext Paris: VLA) and LimmaTech Biologics have entered into a strategic partnership and exclusive licensing agreement to develop, manufacture, and commercialize Shigella4V.
The tetravalent vaccine is under development for shigellosis, a major global health concern which is particularly dangerous for young children and immunocompromised people.
Caused by Shigella bacteria, the disease primarily affects the digestive system and leads to symptoms such as diarrhea, fever, stomach cramps, nausea, and vomiting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze